The firm said that it will use the money for working capital and general corporate purposes, and the raise follows a $3.25 million public offering that closed in May.

ArteraAI Prostate is authorized for use as a tool to prognosticate long-term outcomes for patients with non-metastatic prostate cancer.

NEW YORK – The World Health Organization on Monday released an update to its operational handbook on the diagnosis of tuberculosis that provides laboratory personnel, clinicians, ministries of health, ...

Last week, readers were most interested in a story about Diasorin's preparation to enter the point-of-care molecular testing space with a benchtop instrument.

The target device includes a portable instrument and 30-minute, $5 assays requiring only small volumes of whole capillary blood.

The test is compatible with lateral flow technology and could be used to provide tuberculosis testing in low-resource settings.

The Johns Hopkins University spinout's MycoMeia Aspergillus Assay is used to aid the diagnosis of the lung disease aspergillosis in immunocompromised patients.

The firm's genomics revenues more than doubled year over year, while data and services revenue increased nearly 36 percent.

The firm said it is in talks with payors about pilot programs and it expects to soon publish data on the use of its test to improve outcomes and reduce healthcare costs.

The firm is aiming to accelerate growth in its molecular business by expanding menu and driving adoption of additional testing.